Meanwhile, a series of recent studies by Zuurbier et al. clearly showed that selective SGLT2-inhibitors directly inhibit cardiac NHE [45–47], although empagliflozin did not significantly affect the cardiac functional recovery or myocardial injury after ischemia–reperfusion, which is consistent with our findings; however, the authors did not examine any models of diet-induced obesity [45]. Here, SLC5A2 is linked to obesity disorder.